XML 43 R30.htm IDEA: XBRL DOCUMENT
v3.24.2

Revenue from Contracts with Customers (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2024
Schedule of Contract Assets and Contract Liabilities | Total contract assets at June 30, 2024 were as follows:
(In thousands) |  | Contract Assets |
Contract assets at December 31, 2023 |  | $ | 706 |
Additions |  |  | 4,721 |
Transferred to receivables, net |  |  | (1,935 | )
Contract assets at June 30, 2024 |  | $ | 3,492 |
Total contract liabilities at June 30, 2024 were as follows:
(In thousands) |  | Contract Liabilities |
Contract liabilities at December 31, 2023 |  | $ | 4,775 |
Additions |  |  | 34 |
Amounts recognized into revenue |  |  | (1,498 | )
Contract liabilities at June 30, 2024 |  | $ | 3,311 |
Product sales, net |
Schedule of Disaggregation of Revenues | During the three and six months ended June 30, 2024 and 2023, the Company recorded product sales, net, as follows:
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
(In thousands) |  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
VIVITROL |  | $ | 111,873 |  |  | $ | 102,071 |  |  | $ | 209,532 |  |  | $ | 198,730 |
ARISTADA and ARISTADA INITIO |  |  | 86,049 |  |  |  | 82,409 |  |  |  | 164,919 |  |  |  | 162,486 |
LYBALVI |  |  | 71,351 |  |  |  | 46,997 |  |  |  | 128,358 |  |  |  | 84,988 |
Total product sales, net |  | $ | 269,273 |  |  | $ | 231,477 |  |  | $ | 502,809 |  |  | $ | 446,204 |
Manufacturing and royalty revenues |
Schedule of Disaggregation of Revenues | During the three and six months ended June 30, 2024 and 2023, the Company recorded manufacturing and royalty revenues from its collaboration arrangements as follows:
|  | Three Months Ended June 30, 2024 |  |  | Six Months Ended June 30, 2024 |
(In thousands) |  | Manufacturing Revenue |  |  | Royalty Revenue |  |  | Total |  |  | Manufacturing Revenue |  |  | Royalty Revenue |  |  | Total |
Long-acting INVEGA products(1) |  | $ | — |  |  | $ | 78,739 |  |  | $ | 78,739 |  |  | $ | — |  |  | $ | 141,412 |  |  | $ | 141,412 |
VUMERITY |  |  | 9,863 |  |  |  | 25,371 |  |  |  | 35,234 |  |  |  | 21,987 |  |  |  | 44,501 |  |  |  | 66,488 |
Other |  |  | 10,417 |  |  |  | 5,468 |  |  |  | 15,885 |  |  |  | 28,323 |  |  |  | 10,468 |  |  |  | 38,791 |
|  | $ | 20,280 |  |  | $ | 109,578 |  |  | $ | 129,858 |  |  | $ | 50,310 |  |  | $ | 196,381 |  |  | $ | 246,691 |
|  | Three Months Ended June 30, 2023 |  |  | Six Months Ended June 30, 2023 |
(In thousands) |  | Manufacturing Revenue |  |  | Royalty Revenue |  |  | Total |  |  | Manufacturing Revenue |  |  | Royalty Revenue |  |  | Total |
Long-acting INVEGA products(1) |  | $ | — |  |  | $ | 321,239 |  |  | $ | 321,239 |  |  | $ | — |  |  | $ | 334,801 |  |  | $ | 334,801 |
VUMERITY |  |  | 10,369 |  |  |  | 21,926 |  |  |  | 32,295 |  |  |  | 23,018 |  |  |  | 38,151 |  |  |  | 61,169 |
Other |  |  | 21,529 |  |  |  | 10,850 |  |  |  | 32,379 |  |  |  | 47,320 |  |  |  | 15,485 |  |  |  | 62,805 |
|  | $ | 31,898 |  |  | $ | 354,015 |  |  | $ | 385,913 |  |  | $ | 70,338 |  |  | $ | 388,437 |  |  | $ | 458,775 |
(1) “long-acting INVEGA products”: INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate) and INVEGA HAFYERA/BYANNLI (paliperidone palmitate).

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=alks_ManufacturedProductAndRoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |